MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Cardiovascular / Medtronic touts 1-year Arctic Front cryoballoon study data

Medtronic touts 1-year Arctic Front cryoballoon study data

August 28, 2018 By Fink Densford Leave a Comment

Medtronic's Arctic Front Cryoballoon

Medtronic (NYSE:MDT) today released results from the Cryo4Persistent AF clinical trial of its Arctic Front Advance cryoablation system, touting reductions in the symptoms of abnormal heart rhythms and a low rate of re-interventions and repeat ablations.

The Fridley, Minn.-based company said it presented results from the trial at the 2018 European Society of Cardiology Congress in Munich this week.

“These findings highlight the advantage of cryoballoon ablation in patients with persistent AF, demonstrating that patients have fewer symptoms after treatment and a significant improvement in their quality of life. Paired with the study data showing a low incidence of reinterventions, it’s clear to see the benefit for both patients and healthcare providers,” study co-investigator Dr. K.R. Julian Chun of Frankfurt, Germany’s Agaplesion Markus Hospital said in a prepared statement.

Data from the 101-patient trial indicated that patients treated with cryoballoon ablation showed an average 7.1 point improvement in physical quality of life scores and a 3.3 point average improvement in mental health quality of life scores.

Patients who underwent cryballoon ablation also experienced a significant reduction in symptoms, with 92% experiencing symptoms including dizziness, palpitations and fatigue before the procedure and only 16% at one-year post procedure, Medtronic said.

Severity of symptoms also declined from 2.1 to 1.3 using the European Heart Rhythm Association AF symptom score. A total 47% of patients in the cryoballoon arm also showed NYHA class improvements of one or more functional classes at 12 months, the company said.

Only 17 of the 101 patients in the trial required a repeat ablation at the time of arrhythmia recurrence, and only eight patients underwent direct current cardioversion procedures. Only 3 patients in the trial remained antiarrhythmic medication at the end of the study, Medtronic said.

“The Cryo4Persistent AF study findings complement the growing body of clinical evidence that suggests cryoballoon ablation offers significant benefits to patients with AF even after the disease has progressed. At Medtronic, we’re focused on improving patient outcomes and quality of life, while offering greater efficiencies for physicians treating the growing number of AF patients today,” Medtronic AF solutions biz GM Rebecca Seidel said in a press release.

Last week, Medtronic posted fiscal first-quarter results that topped the consensus forecast on Wall Street and raised its sales outlook for the rest of fiscal 2019.

Filed Under: Cardiovascular, Clinical Trials, Vascular Tagged With: Medtronic

In case you missed it

  • J&J’s Ethicon gets to substitute 20 new claims on surgical stapler patent
  • Minerva Surgical raises $10m
  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • Orthofix names new president of global spine business
  • J&J Vision launches Tecnis Toric II intraocular lens in U.S.
  • NOUS Imaging picks up $6.6m for brain-imaging software
  • MicroVention issues safety notice for Azur endovascular embolization products
  • Study reveals long-term outcomes of Boston Scientific Watchman patients
  • 3M issues safety notice for Durapore Advanced surgical tape
  • FDA clearance positions Sight Diagnostics to deliver on two-drop blood testing promise
  • TransMedics touts first U.S. ‘reanimated’ heart transplants
  • Micro-Leads collects $10m for neuromod therapy
  • Viant to cease ethylene oxide sterilization at Michigan plant by year’s end
  • Venclose closes $27m Series C
  • CSA Medical wins CE Mark approval for RejuvenAir System
  • N2 Biomedical appoints new chief financial officer
  • Senate committee favors Hahn for FDA chief

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS